Dr Manny's Notes

FDA Should Keep Avastin’s Approval for Breast Cancer

Dr. Manny Alvarez

Dr. Manny Alvarez

In December, the Food and Drug Administration drafted a proposal to remove the approval of Avastin for breast cancer treatment. Now, tensions have hit a fever pitch now that the FDA has officially ruled for a second time that the drug should no longer be used in breast cancer patients.

The FDA first approved Avastin for breast cancer in 2008 after a study showed the drug stalled cancer growth by almost six months when used in combination with chemotherapy. Because the drug was given accelerated approval, the FDA required Roche to run follow-up studies to confirm the drug’s effectiveness.

However, the later studies weren’t as successful, finding only a one to three month delay in cancer growth. None proved that Avastin extended the lives of patients with advanced breast cancer, and some patients had severe side effects such as holes in the stomach and intestines.

Nevertheless, when the FDA began its hearing for Avastin on Tuesday, breast cancer patients started to step forward to recount their success stories, thanks in part, to the drug. Some have held signs and chanted outside the FDA building in favor of Avastin.

Personally, I agree with these patients. I think that the FDA should have kept the approval of Avastin for breast cancer, pending new studies.

Metastatic breast cancer, in many cases, is very difficult to treat, and the choices of treatments are often limited.

I am aware of the discrepancies in cancer survival rates with the use of Avastin. However, there are some patients that do show significant improvement after taking it, and it is unfair to have the drug’s approval removed for this use when there is a select group of women that could definitely benefit from it.

Medical treatment, especially for something as complicated as metastatic cancer, has to keep whatever positive gains toward a cure it has and build upon that to get to newer drugs and better treatments with higher degrees of success.

Now, even without FDA approval of Avastin for metastatic breast cancer, doctors can still utilize the drug. However, Medicare may not cover its costs, and certainly many private insurance agencies may think twice before approving claims for it. This ruling is devastating for the 17,000 breast cancer patients out there that are currently taking Avastin.

Because, really, at the end of the day, it is the patients and their families who will be hurt the most.

Dr. Manny Alvarez serves as Fox News Channel's senior managing health editor. He also serves as chairman of the department of obstetrics/gynecology and reproductive science at Hackensack University Medical Center in New Jersey. For more information on Dr. Manny's work, visit AskDrManny.com.